Protagonist Therapeutics ...

48.88
-0.56 (-1.13%)
At close: Mar 28, 2025, 3:59 PM
48.88
0.00%
After-hours: Mar 28, 2025, 04:34 PM EDT

Company Description

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.

It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.

The company has a license and collaboration agreement with Janssen Biotech, Inc.

Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc. logo
Country United States
IPO Date Aug 11, 2016
Industry Biotechnology
Sector Healthcare
Employees 126
CEO Dr. Dinesh V. Patel Ph.D.

Contact Details

Address:
7707 Gateway Boulevard
Newark, California
United States
Website https://www.protagonist-inc.com

Stock Details

Ticker Symbol PTGX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001377121
CUSIP Number 74366E102
ISIN Number US74366E1029
Employer ID 98-0505495
SIC Code 2834

Key Executives

Name Position
Dr. Dinesh V. Patel Ph.D. Chief Executive Officer, President, Secretary & Director
Asif Ali Executive Vice President & Chief Financial Officer
Abha Bommireddi Executive Vice President of Portfolio & Program Management
Carena Spivey Head of HR & Senior Vice President of Human Resources
Carter J. King Executive Vice President of Business Development
Dr. Ashok Bhandari Ph.D. Executive Vice President & Chief Drug Discovery and Preclinical Development Officer
Dr. Newman Yeilding EVice President, Chief Scientific Officer
Dr. Suneel K. Gupta Ph.D. Executive Vice President of Clinical Development
Matthew M. Gosling J.D. Executive Vice President & General Counsel
Mohammad Masjedizadeh Ph.D. Executive Vice President & Chief Technical Officer

Latest SEC Filings

Date Type Title
Mar 20, 2025 8-K Current Report
Mar 19, 2025 4 Filing
Mar 14, 2025 4 Filing
Mar 14, 2025 4 Filing
Mar 11, 2025 8-K/A [Amend] Current Report
Mar 10, 2025 8-K Current Report
Mar 05, 2025 4 Filing
Mar 03, 2025 8-K Current Report
Feb 21, 2025 S-8 Filing
Feb 21, 2025 10-K Annual Report